NV-ROBOSENSE
8.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense (http://www.robosense.ai ), the leading autonomous driving LiDAR perception solution provider, announced today the world’s first public road test of a vehicle equipped with a Smart LiDAR Sensor at CES 2020 . The RoboSense Smart LiDAR car, featuring the award-winning RS-LiDAR-M1 Smart LiDAR , will be running outside the Las Vegas Convention Center daily during CES 2020, showing the latest technological progress in autonomous vehicle LiDAR. Simultaneous exhibitions will be held at RoboSense’s CES Booth #6138 at the LVCC, North Hall showcasing the real-time 3D point cloud data on a vehicle equipped with the multi solid state LiDAR fusion system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005303/en/
First MEMS Smart LiDAR Sensor to Incorporate Sensor Hardware, AI Perception Algorithms, & IC Chipsets
The RoboSense RS-LiDAR-M1 Smart LiDAR is the world’s first MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 is the winner of the CES Innovation Award for two consecutive years in a row, 2019 and 2020.
RoboSense Co-Partner and Vice President of R&D, Dr. Leilei Shinohara, said, “After optimization based on large amounts of data, RoboSense’s algorithm performance and software stability and reliability have proven to have many key advantages. Developed by RoboSense after more than a decade of exhaustive research in perception technology, it has combined the advantages of deep-learning-based AI algorithm with the traditional algorithms to keep functional safety. Since 2017, RoboSense’s algorithms have gained more than 100 global partners for various types of autonomous driving scenario certifications.”
At CES and on the streets of Las Vegas, the RoboSense RS-LiDAR-M1 Smart is demonstrating that it is the world’s first and only Smart LiDAR capable of real road tests on open roads .
128 Laser Beam System & Fastest Mass-produced Short-range LiDAR for Blind Spot Detection
During CES 2020, RoboSense128-beams LiDAR RS-Ruby and the short-range Blind Spot LiDAR RS-BPearl also go on public road demo, meanwhile there is also a simultaneous exhibition at RoboSense Booth. This super high-performance 128-beam LiDAR RS-Ruby possesses an ultra-high resolution of 0.1° and the range performance of 200m for a 10% reflectivity target.
The RS-BPearl, the first mass-produced short-range LiDAR for blind-spot detection, reaches the minimum detection range of less than several centimeters, with hemispheric FOV coverage of 90° * 360°, which not only precisely identifies objects around the vehicle’s body, but can also detect the actual height information in particular scenarios, such as with bridge tunnels and culverts.
RoboSense Partner Demonstrations at CES 2020
RoboSense has partnerships with numerous industry leaders who will be announcing partnerships or co-demonstrating with RoboSense at CES, including ON Semiconductor, Xilinx, Horizon, AutoX, and Freetech.
Wade Appelman, Vice President of ISG, SensL Division, ON Semiconductor, said, “The combo of RoboSense LiDAR with the ON Semiconductor RD Series SiPM family of products will perform much better than the older APD technology employed by legacy LiDAR manufacturers using mechanical scanning architectures, further enhancing the performance of the RS-LiDAR-M1 to be one of the best in the automotive LiDAR market.”
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
